Skip to main content

Table 2 Concomitant therapy with methotrexate at start of treatment with etanercept

From: Re-treatment with etanercept is as effective as the initial firstline treatment in patients with juvenile idiopathic arthritis

 

1st ETA course, n = 1724

2nd ETA course, n = 338

3rd ETA course, n = 54

All JIA

1197 (69.4%)

133 (39.4%)

15 (27.6%)

Systemic JIA

91 (82.0%)

12 (54.6%)

3 (75.0%)

Polyarticular arthritis, RF-negative

370 (76.0%)

40 (40.0%)

7 (33.3%)

Polyarticular arthritis RF-positive

142 (80.7%)

9 (36.0%)

2 (50.0%)

Persistent Oligoarthritis

50 (68.5%)

8 (57.1%)

0 (0.0%)

Extended Oligoarthritis

204 (66.5%)

25 (36.2%)

1 (11.1%)

Enthesitis-related arthritis

190 (52.9%)

25 (38.5%)

1 (11.1%)

Psoriatic arthritis

109 (73.7%)

10 (30.3%)

1 (50.0%)

Undifferentiated arthritis

41 (65.1%)

4 (40.0%)

0 (0.0%)

MTX at ETA stop/last observation

631 (36.6%)

79 (23.4%)

8 (14.8%)

Ever concomitant treatment with MTX

1239 (71.9%)

144 (42.6%)

15 (27.8%)

Duration of concomitant MTX therapy since start of ETA in patients who stopped MTX in years, mean (SD)

1.5 (1.6)

0.8 (1.5)

0.2 (0.3)

  1. ETA etanercept, MTX methotrexate, RF rheumatoid factor, SD standard deviation